癌症纳米药物的相对低成功率引起了对增强通透性和滞留效应（EPR效应）在提高药物输送到肿瘤和改善治疗效果中作用的争议。在本综述中，我们突出了超越EPR效应的增强纳米粒子输送到肿瘤的新策略。我们讨论了横穿细胞渗透、受体介导途径和蛋白质冠层相互作用对纳米粒子在肿瘤中沉积的作用。我们总结了铂类联合纳米药物在包含多种化疗药物具有协同抗癌机制和多种采用新机制的抗癌疗法中的最新进展，以增强药物输送和抗肿瘤活性。我们还突出了铂类联合纳米药物未来的机会以及这些联合纳米药物进入临床的关键障碍。Copyright © 2023 Elsevier Ltd. All rights reserved.

The relatively low success rate of cancer nanomedicines has raised debate on the roles of the enhanced permeability and retention (EPR) effect in enhancing drug delivery to tumors and improving therapeutic efficacy. In this review, we highlight new strategies beyond the EPR effect for enhancing nanoparticle delivery to tumors. We discuss the roles of transcellular extravasation, receptor-mediated pathways, and protein corona interactions on nanoparticle deposition in tumors. We summarize recent progress in platinum-based combination nanomedicines containing multiple chemotherapeutics with synergistic anticancer mechanisms and multiple anticancer therapies with novel mechanisms to enhance drug delivery and antitumor activities. We also highlight future opportunities in platinum-based combination nanomedicines and key hurdles for the translation of these combination nanomedicines into the clinic.Copyright © 2023 Elsevier Ltd. All rights reserved.